Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LL1N
|
|||
| Drug Name |
ADCT-301
|
|||
| Synonyms |
camidanlumab tesirine
Click to Show/Hide
|
|||
| Indication | Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9; ICD-9: 201] | Phase 2 | [1] | |
| Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1 | [2] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2], [3] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [3] | ||
| Company |
ADC Therapeutics Murray Hill, NJ
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04052997) Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.